Soy Lecithin.

Commercial phosphatidylcholine has long been fractionated from soy lecithin. The lecithin and the purified fraction deliver the same molecule at different concentrations.

Soy lecithin contains phosphatidylinositol alongside phosphatidylcholine and phosphatidylethanolamine. The isolated inositol phospholipid is a concentrate of a fraction already present.

Digestive phospholipases release choline from phosphatidylcholine, so soy lecithin feeds the same body pool as a free choline salt. Release is slower and steadier from the phospholipid.

Soy phospholipids are the carrier in the phytosome approach, where curcuminoids are complexed with phosphatidylcholine so the particle presents a lipid surface to the intestinal membrane rather than a poorly wetted crystal.

Carotenoid uptake depends on partitioning into mixed micelles with bile salts and phospholipids. Lecithin supplies the phospholipid side of that micelle, which is why it is a routine excipient in carotenoid softgels.

Citicoline is the direct intermediate the Kennedy pathway uses to build phosphatidylcholine. Lecithin supplies the finished phospholipid while citicoline supplies the intermediate one step upstream.

The PEMT route builds phosphatidylcholine by transferring three methyl groups from S-adenosylmethionine, which folate helps regenerate. Dietary lecithin lowers how heavily that methyl-consuming route is used.

Lecithin phospholipids are one of the two structural components of an intestinal mixed micelle, bile salts being the other. Where bile delivery is limited, the emulsifying contribution of dietary phospholipid does not get completed into micelles. The relationship is textbook lipid digestion, described here as physiology rather than as a tested supplement pairing.

Intact phosphatidylcholine is not absorbed as such. Phospholipase A2 removes one acyl chain, and the resulting lyso-phosphatidylcholine is taken up and re-acylated inside the enterocyte. Pancreatic enzyme activity therefore sits directly upstream of what lecithin delivers.

Vitamin D3 is lipophilic and needs a lipid vehicle and micelle formation to reach the enterocyte membrane. Lecithin is a standard emulsifier used to disperse it in softgels and emulsions. The absorption principle is established; the size of the gain depends on the specific formulation and dose.

MK-7 partitions into fat and travels in lipoproteins, so it is poorly absorbed from a dry powder taken without lipid. Lecithin provides both the lipid and the emulsifier in one excipient. This is formulation physiology rather than a clinical outcome claim.

Soy lecithin is rich in linoleic acid, which oxidises readily and gives lecithin its characteristic off-odour when it degrades. Tocopherol is a standard chain-breaking antioxidant added to slow that. The benefit is to the material's stability, and it is also the reason lecithin improves tocopherol dispersion in return.

Retinyl esters are hydrolysed at the brush border and the released retinol enters the enterocyte from a mixed micelle. Lecithin contributes to forming that micelle and keeps the vitamin dispersed in the dosage form. Established physiology, stated as absorption support and not as an outcome.

Lutein is a lipophilic pigment whose absorption rises when it is delivered with fat and an emulsifier rather than as a dry crystal. Lecithin-based dispersions are a common formulation answer. The mechanism is well established for carotenoids as a class.

Solid crystalline ubiquinone dissolves very poorly in intestinal fluid, which is the rate-limiting step for its absorption. Lecithin-containing oil dispersions and phospholipid complexes keep it in solution. This is a formulation-level statement about dissolution, not a claim about a clinical endpoint.

Lecithin is an emulsifier that keeps fish oil dispersed in emulsions and reduces phase separation. Both materials carry oxidation-prone chains, so an antioxidant system is needed for the pair rather than for either alone. The point is formulation stability and dispersion.

Medium-chain triglycerides dissolve lipophilic actives and disperse readily, and lecithin lowers interfacial tension so the droplets stay fine. Together they form the base of many self-emulsifying delivery systems. The claim is about the vehicle, not about either ingredient's own activity.

Lecithin-derived phosphatidylcholine feeds the choline pool, part of which is oxidised in liver and kidney to betaine. Betaine itself supplies the methyl group in the BHMT route of homocysteine remethylation, so supplying it directly spares choline for its structural roles. Supporting normal homocysteine metabolism is the structure-function frame; no combination trial in this candidate set tested the pair.

Homocysteine is remethylated either by B12-dependent methionine synthase using 5-methyltetrahydrofolate, or by BHMT using betaine derived from choline. Because lecithin supplies choline, it supports the second route while B12 supports the first. That parallel structure is settled biochemistry; it is a description of the pathway, not a measured clinical effect.

When folate-dependent remethylation is constrained, more homocysteine is handled through the choline-betaine route, and the same shift runs in the other direction as well. Lecithin-derived phosphatidylcholine is one of the main dietary contributions to that choline pool. The interdependence is well established; how much a given lecithin dose shifts the balance in people is not established.

Silymarin dissolves badly in water, which limits how much reaches the enterocyte. Complexing it with phospholipid changes its dispersion behaviour and is the basis of the phospholipid-complex products in this category. The claim is about the delivery system for the partner, not about lecithin having that activity itself.

Quercetin aglycone is close to insoluble in water, so dissolution governs its absorption. Lecithin-based complexes and dispersions improve wetting and keep it from recrystallising in the dosage form. This is a delivery observation, and the size of the effect depends on how the complex is made.